# Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

> **NCT01170650** · PHASE3 · TERMINATED · sponsor: **Endocyte** · enrollment: 441 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** EC145
- **DRUG:** Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)
- **DRUG:** placebo
- **DRUG:** EC20

## Key facts

- **NCT ID:** NCT01170650
- **Lead sponsor:** Endocyte
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04-22
- **Primary completion:** 2015-05-31
- **Final completion:** 2015-09-08
- **Target enrollment:** 441 (ACTUAL)
- **Why stopped:** DSMB decision
- **Last updated:** 2021-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01170650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01170650, "Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01170650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*